Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells

Authors: Rihong Cong, Qingmin Sun, Li Yang, Haijuan Gu, Ying Zeng, Bin Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

Vasculogenic mimicry (VM) was increasingly recognized as a form of aggressive melanoma acquiring blood supply. Genistein had attracted much attention as a potential anticancer agent. Therefore, we examined the effect of Genistein on VM in human uveal melanoma cells.

Methods

VM structure was detected by periodic acid-Schiff (PAS) staining for uveal melanoma C918 cells cultured on the three-dimensional type I collagen gels after exposed to Genistein. We used reverse transcription polymerase chain reaction (RT-PCR) and Western Blot analysis to examine the effect of Genistein on vascular endothelial cadherin (VE-cadherin) mRNA and protein expression. The nude mice models of human uveal melanoma C918 cells were established to assess the number of VM using immunohistochemical and PAS double-staining.

Results

Genistein inhibited the survival of C918 cells in vitro. The ectopic model study showed that VM in tumor tissue sections were significantly reduced by Genistein in vivo. In vitro, the VM structure was found in control, 25 and 50 μM Genistein-treatment groups but not in 100 and 200 μM. RT-PCR and Western Blot showed that 100 and 200 μM concentration of Genistein could significantly decrease VE-cadherin mRNA and protein expression of C918 cells compared with control (P < 0.05). However, the 25 and 50 μM Genistein slightly decreased the VE-cadherin level in vitro (P > 0.05).

Conclusion

Genistein inhibits VM formation of uveal melanoma cells in vivo and in vitro. One possible underlying molecular mechanism by which Genistein could inhibit VM formation of uveal melanoma is related to down-regulation of VE-cadherin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Folkman J: Clinical applications of research on angiogenesis. Seminars in Medicine of the Beth Israel Hospital, Boston. New Engl J Med. 1995, 333: 1757-1763. 10.1056/NEJM199512283332608.CrossRef Folkman J: Clinical applications of research on angiogenesis. Seminars in Medicine of the Beth Israel Hospital, Boston. New Engl J Med. 1995, 333: 1757-1763. 10.1056/NEJM199512283332608.CrossRef
2.
go back to reference Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L: Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006, 13: 549-556. 10.1016/j.chembiol.2005.12.009.CrossRef Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L: Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006, 13: 549-556. 10.1016/j.chembiol.2005.12.009.CrossRef
3.
go back to reference Schaft Van der DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004, 96: 1473-1477. 10.1093/jnci/djh267.CrossRef Schaft Van der DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004, 96: 1473-1477. 10.1093/jnci/djh267.CrossRef
4.
go back to reference Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, Trent JM, Meltzer PS, Hendrix MJC: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155: 739-752.CrossRef Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, Trent JM, Meltzer PS, Hendrix MJC: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155: 739-752.CrossRef
5.
go back to reference Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Cohen MB, Lubaroff DM, Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002, 50: 189-201. 10.1002/pros.10048.CrossRef Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Cohen MB, Lubaroff DM, Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002, 50: 189-201. 10.1002/pros.10048.CrossRef
6.
go back to reference Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62: 560-566. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62: 560-566.
7.
go back to reference Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ: Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001, 158: 1279-1288.CrossRef Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ: Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001, 158: 1279-1288.CrossRef
8.
go back to reference Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L: Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008, 39: 444-451. 10.1016/j.humpath.2007.07.018.CrossRef Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L: Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008, 39: 444-451. 10.1016/j.humpath.2007.07.018.CrossRef
9.
go back to reference McLean IW: The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol. 1993, 422: 433-437. 10.1007/BF01606450.CrossRef McLean IW: The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol. 1993, 422: 433-437. 10.1007/BF01606450.CrossRef
10.
go back to reference Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG, Armstrong BK: Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 2003, 105: 117-122. 10.1002/ijc.11057.CrossRef Vajdic CM, Kricker A, Giblin M, McKenzie J, Aitken J, Giles GG, Armstrong BK: Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 2003, 105: 117-122. 10.1002/ijc.11057.CrossRef
11.
go back to reference Davis JN, Singh B, Bhuiyan M, Sarkar FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998, 32: 123-131. 10.1080/01635589809514730.CrossRef Davis JN, Singh B, Bhuiyan M, Sarkar FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998, 32: 123-131. 10.1080/01635589809514730.CrossRef
12.
go back to reference Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH: Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer. 1998, 31: 184-191. 10.1080/01635589809514701.CrossRef Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH: Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer. 1998, 31: 184-191. 10.1080/01635589809514701.CrossRef
13.
go back to reference Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH: Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer. 1999, 34: 12-19. 10.1207/S15327914NC340102.CrossRef Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH: Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer. 1999, 34: 12-19. 10.1207/S15327914NC340102.CrossRef
14.
go back to reference Upadhyay S, Neburi M, Chinni SR, Alhasan S, Miller F, Sarkar FH: Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin Cancer Res. 2001, 7: 1782-1789. Upadhyay S, Neburi M, Chinni SR, Alhasan S, Miller F, Sarkar FH: Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin Cancer Res. 2001, 7: 1782-1789.
15.
go back to reference Pepper MS, Hazel SJ, Humpel M, Schleuning WD: 8-Prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. Journal of Cellular Physiology. 2004, 199: 98-107. 10.1002/jcp.10460.CrossRef Pepper MS, Hazel SJ, Humpel M, Schleuning WD: 8-Prenylnaringenin, a novel phytoestrogen, inhibits angiogenesis in vitro and in vivo. Journal of Cellular Physiology. 2004, 199: 98-107. 10.1002/jcp.10460.CrossRef
16.
go back to reference Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL: Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther. 2005, 21: 107-113. 10.1089/jop.2005.21.107.CrossRef Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL: Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther. 2005, 21: 107-113. 10.1089/jop.2005.21.107.CrossRef
17.
go back to reference Wang B, Zou Y, Yuan ZL, Xiao JG: Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul pharmcol Ther. 2003, 19: 457-464. 10.1089/108076803322473015.CrossRef Wang B, Zou Y, Yuan ZL, Xiao JG: Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul pharmcol Ther. 2003, 19: 457-464. 10.1089/108076803322473015.CrossRef
18.
go back to reference Wang B, Li H, Pan JS, Yan H: Genistein inhibited hypoxia inducible factor-1α expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Method Find Exp Clin Pharmacol. 2005, 27: 179-184. 10.1358/mf.2005.27.3.890875.CrossRef Wang B, Li H, Pan JS, Yan H: Genistein inhibited hypoxia inducible factor-1α expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Method Find Exp Clin Pharmacol. 2005, 27: 179-184. 10.1358/mf.2005.27.3.890875.CrossRef
19.
go back to reference Pan JS, Zhu HJ, Zhang B, Li H, Yan H, Wang B: Inhibitive effect of genistein on hypoxia-induced basic fibroblast growth factor expression in human retinal pigment epithelium cells. J Ocul Pharmacol Ther. 2006, 22: 103-109. 10.1089/jop.2006.22.103.CrossRef Pan JS, Zhu HJ, Zhang B, Li H, Yan H, Wang B: Inhibitive effect of genistein on hypoxia-induced basic fibroblast growth factor expression in human retinal pigment epithelium cells. J Ocul Pharmacol Ther. 2006, 22: 103-109. 10.1089/jop.2006.22.103.CrossRef
20.
go back to reference Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA. 2001, 98: 8018-8023. 10.1073/pnas.131209798.CrossRef Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA. 2001, 98: 8018-8023. 10.1073/pnas.131209798.CrossRef
21.
go back to reference Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003, 995: 151-161. 10.1111/j.1749-6632.2003.tb03218.x.CrossRef Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003, 995: 151-161. 10.1111/j.1749-6632.2003.tb03218.x.CrossRef
22.
go back to reference Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther. 2002, 1: 1173-1179. Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther. 2002, 1: 1173-1179.
23.
go back to reference Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, Li S: Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest. 2008, 26: 359-368. 10.1080/07357900701788106.CrossRef Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, Li S: Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest. 2008, 26: 359-368. 10.1080/07357900701788106.CrossRef
24.
go back to reference Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y, Wang Y: Doxycycline influences microcirculation patterns in B16 melanoma. Exp Biol Med (Maywood). 2007, 232: 1300-1307. 10.3181/0705-RM-145.CrossRef Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y, Wang Y: Doxycycline influences microcirculation patterns in B16 melanoma. Exp Biol Med (Maywood). 2007, 232: 1300-1307. 10.3181/0705-RM-145.CrossRef
25.
go back to reference Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y, Hendrix MJ: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 2003, 63: 5381-5389. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y, Hendrix MJ: Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 2003, 63: 5381-5389.
26.
go back to reference Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7: R422-435. 10.1186/bcr1019.CrossRef Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7: R422-435. 10.1186/bcr1019.CrossRef
27.
go back to reference Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003, 63: 4757-4762. Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003, 63: 4757-4762.
28.
go back to reference Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y, Sun B: Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res. 2008, 27: 60-10.1186/1756-9966-27-60.CrossRef Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y, Sun B: Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res. 2008, 27: 60-10.1186/1756-9966-27-60.CrossRef
29.
go back to reference Dixon RA, Ferreira D: Genistein. Phytochemistry. 2002, 60: 205-211. 10.1016/S0031-9422(02)00116-4.CrossRef Dixon RA, Ferreira D: Genistein. Phytochemistry. 2002, 60: 205-211. 10.1016/S0031-9422(02)00116-4.CrossRef
30.
go back to reference Farina HG, Pomies M, Alonso DF, Gomez DE: Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep. 2006, 16: 885-891. Farina HG, Pomies M, Alonso DF, Gomez DE: Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep. 2006, 16: 885-891.
31.
go back to reference Record IR, Broadbent JL, King RA, Dreosti IE, Head RJ, Tonkin AL: Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. Int J Cancer. 1997, 72: 860-864. 10.1002/(SICI)1097-0215(19970904)72:5<860::AID-IJC24>3.0.CO;2-B.CrossRef Record IR, Broadbent JL, King RA, Dreosti IE, Head RJ, Tonkin AL: Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. Int J Cancer. 1997, 72: 860-864. 10.1002/(SICI)1097-0215(19970904)72:5<860::AID-IJC24>3.0.CO;2-B.CrossRef
32.
go back to reference Boccellino M, Camussi G, Giovane A, Ferro L, Calderaro V, Balestrieri C, Quagliuolo L: Platelet-activating factor regulates cadherin-catenin adhesion system expression and beta-catenin phosphorylation during Kaposi's sarcoma cell motility. Am J Pathol. 2005, 166: 1515-1522.CrossRef Boccellino M, Camussi G, Giovane A, Ferro L, Calderaro V, Balestrieri C, Quagliuolo L: Platelet-activating factor regulates cadherin-catenin adhesion system expression and beta-catenin phosphorylation during Kaposi's sarcoma cell motility. Am J Pathol. 2005, 166: 1515-1522.CrossRef
33.
go back to reference Piao M, Mori D, Satoh T, Sugita Y, Tokunaga O: Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium. 2006, 13: 249-266. 10.1080/10623320600903940.CrossRef Piao M, Mori D, Satoh T, Sugita Y, Tokunaga O: Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium. 2006, 13: 249-266. 10.1080/10623320600903940.CrossRef
34.
go back to reference Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997, 57: 2916-2921. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997, 57: 2916-2921.
35.
go back to reference Clarijs R, Otte-Höller I, Ruiter DJ, de Waal RM: Presence of a fluidconducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci. 2006, 43: 912-918. Clarijs R, Otte-Höller I, Ruiter DJ, de Waal RM: Presence of a fluidconducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci. 2006, 43: 912-918.
36.
go back to reference Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, Watanabe I, Heike Y, Togashi K, Konishi J, Brechbiel MW, Wakasugi H: Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrastenhanced dynamic MRI with the macromolecular contrast agent G6-(1B4MGd)(256). Cancer Res. 2002, 62: 860-866. Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, Watanabe I, Heike Y, Togashi K, Konishi J, Brechbiel MW, Wakasugi H: Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrastenhanced dynamic MRI with the macromolecular contrast agent G6-(1B4MGd)(256). Cancer Res. 2002, 62: 860-866.
37.
go back to reference Maniotis AJ, Chen X, Garcia C, DeChristopher PJ, Wu D, Pe'er J, Folberg R: Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Invest. 2002, 82: 1031-1043.CrossRef Maniotis AJ, Chen X, Garcia C, DeChristopher PJ, Wu D, Pe'er J, Folberg R: Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Invest. 2002, 82: 1031-1043.CrossRef
38.
go back to reference Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002, 99: 821-828. 10.1002/ijc.10423.CrossRef Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002, 99: 821-828. 10.1002/ijc.10423.CrossRef
39.
go back to reference Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62: 560-566. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002, 62: 560-566.
Metadata
Title
Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells
Authors
Rihong Cong
Qingmin Sun
Li Yang
Haijuan Gu
Ying Zeng
Bin Wang
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-124

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine